Login
Cara Therapeutics NASDAQ: CARA
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to fundamentally change the way acute pain, chronic pain and pruritus are managed
| Name | Cara Therapeutics |
| Ticker | CARA |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Cannabinoid Therapeutics |
|
Price
52W Low/High |
13.20
12.34 / 29.19 |
| Momentum | Sharp Down |
| Market cap | 658 M |
| 1Y Total Return |
-12.23%
Weak |
| 1Y Volatility |
76.14%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to fundamentally change the way acute pain, chronic pain and pruritus are managed
Details
| Ticker | CARA |
| Name | Cara Therapeutics |
| ISIN | US1407551092 |
| CUSIP | 140755109 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Cannabinoid Therapeutics |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 5/14/21
| Close Price | 13.20 |
| 52W Low/High | 12.34 / 29.19 |
| Market cap | 658 M |
| 1Y Total Return |
-12.23%
Weak |
| 1Y Volatility |
76.14%
High Risk |
| Beta | 2.81 |
| PE (trailing) |
40.00
Above Average |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | 10.9% |
| Cash from Op. / Cur. Liabilities | 0.55 |
| Diluted Earnings / Share | 0.33 |
| ROE | 7.2% |
| ROIC | 7.5% |
| Price / Revenue | 5.1 |
| Price / Book | 2.9 |
| Price / CF | 72.4 |
| Current Ratio | 11.4 |
| Cur.Liabilities / Tot.Liabilities | 0.8 |
| Financial Leverage | 0.02 |
| in Mils USD |
rolling-year up to March
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Revenue |
129
|
24
|
18
|
0
|
1
|
3
|
|
| Gross Profit |
129
|
24
|
18
|
-
|
1
|
3
|
|
| R&D |
93
|
124
|
86
|
41
|
62
|
26
|
|
| EBITDA |
15
|
-113
|
-79
|
-52
|
-68
|
-30
|
|
| Operating Income |
12
|
-119
|
-83
|
-54
|
-70
|
-31
|
|
| Net Income exc. Extra |
14
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
50
|
47
|
40
|
33
|
27
|
27
|
|
| EPS exc. Extra |
0.33
|
-2.55
|
-2.11
|
-1.61
|
-2.52
|
-1.19
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Total Assets |
250
|
196
|
171
|
81
|
43
|
102
|
|
| Cash, Eq & Invt ShortTerm |
172
|
121
|
135
|
75
|
38
|
98
|
|
| Total Current Assets |
188
|
133
|
144
|
79
|
41
|
99
|
|
| Total Non-Current Assets |
62
|
64
|
26
|
2
|
2
|
3
|
|
| Intangibles |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
20
|
36
|
56
|
9
|
14
|
7
|
|
| Total Current Liabilities |
17
|
33
|
42
|
7
|
13
|
6
|
|
| Long Term Debt |
3
|
3
|
14
|
2
|
2
|
1
|
|
| Shareholder equity |
230
|
160
|
115
|
72
|
29
|
95
|
|
| Cash Flow | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Cash from Operations |
9
|
-120
|
-31
|
-52
|
-59
|
-26
|
|
| Depreciation |
1
|
1
|
0
|
0
|
1
|
1
|
|
| Cash from Investing |
-43
|
-20
|
-77
|
-31
|
57
|
-89
|
|
| Capex |
0
|
0
|
0
|
0
|
1
|
0
|
|
| Cash from Financing |
40
|
142
|
111
|
88
|
0
|
76
|
|
| Stock Issued |
40
|
142
|
111
|
88
|
0
|
76
|
|
| Debt (LT) Issued |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Free Cash Flow |
79
|
-106
|
-105
|
-88
|
-5
|
-115
|
|
| Ratios | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Net Profit Margin |
10.9%
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
76.9%
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
11.4
|
4.1
|
3.4
|
11.5
|
3.3
|
16.3
|
|
| Financial Leverage D/E |
0.02
|
0.03
|
0.04
|
0.00
|
0.00
|
0.00
|
|
| Return on Capital Avg |
7.5%
|
-87.1%
|
-90.6%
|
-123.9%
|
-123.7%
|
-70.1%
|
|
| Return on Shareholder Equity |
7.2%
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available